What is tirzepatide, the medication in Mounjaro and Zepbound?

Tirzepatide is a medication that binds to and activates two receptors, GIP and GLP-1, the targets for the body's own GIP and GLP-1. It is the medication in Mounjaro, approved for adults and children 10 and older with type 2 diabetes, and in Zepbound, approved for reducing excess weight and for obstructive sleep apnea in certain adults (Zepbound prescribing information; Mounjaro prescribing information).

This guide explains published facts and prices. It is not medical advice: a licensed provider who knows your health history decides what is right for you.

Is tirzepatide a GLP-1?

Yes, and more than that. The Zepbound label calls tirzepatide a GIP receptor and GLP-1 receptor agonist, so it is a GLP-1 medication that also acts on a second receptor, GIP (Zepbound prescribing information).

The label says nonclinical studies, meaning lab and animal research, suggest the added GIP may further contribute to the regulation of food intake (Zepbound prescribing information). For what GLP-1 itself does, see what is a GLP-1, and for how tirzepatide compares with semaglutide, see semaglutide or tirzepatide.

Is tirzepatide the same as Zepbound?

Zepbound is one brand of tirzepatide, and Mounjaro is another. The medication is the same, but each label lists its own approved uses:

If a price list says only "tirzepatide," ask which of these it is, or whether it is a compounded product.

How is tirzepatide taken?

The Zepbound label sets the same starting schedule for all of its uses (Zepbound prescribing information):

Mounjaro has its own label, so ask your provider about the schedule for the product you are prescribed.

What did the tirzepatide weight loss trial find?

In a trial published in 2022, 2,539 adults without diabetes, each with a body-mass index (BMI) of 30 or more, or 27 or more with at least one weight-related complication, were randomly assigned in four equal groups to once-weekly tirzepatide injections of 5 mg, 10 mg or 15 mg under the skin, or a placebo, for 72 weeks. The first 20 weeks were spent stepping up the dose (New England Journal of Medicine, 2022).

By week 72, people had lost an average of 15.0% of their body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, compared with 3.1% on placebo. The most common side effects with tirzepatide were digestive (gastrointestinal), most were mild to moderate, and they occurred mainly while the dose was being stepped up (New England Journal of Medicine, 2022).

Those are group averages from one trial, not a forecast for you. Ask your provider what they mean for your situation.

Is tirzepatide safe?

The Zepbound label answers with facts, not a yes or a no: who it is approved for, which is above, and these warnings, which a licensed provider weighs for one person (Zepbound prescribing information):

The most common side effects, reported in at least 5% of people taking Zepbound, are nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, burping, hair loss and acid reflux (Zepbound prescribing information).

What about compounded tirzepatide?

A monthly tirzepatide price at a med spa may not be for Zepbound or Mounjaro. FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug (FDA's concerns with unapproved GLP-1 drugs). What else FDA says about compounded and unapproved versions is in what is a GLP-1.

So ask: is this Zepbound, Mounjaro or a compounded product, who prescribes it, and which pharmacy fills it?

What does tirzepatide cost at a Georgia med spa?

These are estimates from what Georgia med spas and skin clinics publish, not quotes, and we do not name any company.

Because the dose is stepped up over time, ask whether the monthly price changes with it.

Questions to ask your provider

Ask for the product name and each month's price in writing before you begin.

Sources

  1. Zepbound (tirzepatide) injection, FDA-approved prescribing information (Eli Lilly, label effective August 2026), DailyMed, National Library of Medicine
  2. Mounjaro (tirzepatide) injection, FDA-approved prescribing information (Eli Lilly, label effective August 2026), DailyMed, National Library of Medicine
  3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216
  4. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration

Prices mentioned here come from our Georgia med spa cost ranges, built from the prices and cost guides Georgia med spas publish on their public websites, collected September and October 2026.

Find a Georgia med spa